Results 171 to 180 of about 38,022 (310)

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source

Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation. [PDF]

JAMA
Maya J, Pant D, Fu Y, James K, Batlle C, Hsu S, Soria-Contreras DC, Shook LL, Mow C, Hivert MF, Thaweethai T, Powe CE.   +11 more
europepmc   +1 more source

Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Despite the established efficacy of tirzepatide in randomised controlled trials, real‐world effectiveness data in Japanese patients remain limited. This study evaluated the real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes over 52 weeks.
Yusuke Minakata, Masaki Miura, Nobuhiro Nakatake, Masahiro Masuzawa   +3 more
wiley   +1 more source

Perioperative GLP-1 Receptor Agonist Use is Associated With Reduced Revisions and Complications Following ACDF: A Propensity-Matched Analysis. [PDF]

Global Spine J
Kim MT, Lee S, Goh GS, Riew KD.
europepmc   +1 more source

Seizure recurrence after GLP‐1 receptor agonist initiation in adults with epilepsy

Epilepsia, EarlyView.
Abstract Objective To examine whether initiation of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) is associated with seizure recurrence and related outcomes in adults with epilepsy and type 2 diabetes. Methods We conducted a retrospective cohort study using de‐identified electronic health records from the TriNetX Research Network (January 2003 ...
Majd A. AbuAlrob, Abdullah Hussein, Rand Abdellatif, Adham Itbaisha, Khaled Zammar, Boulenouar Mesraoua   +5 more
wiley   +1 more source

Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. [PDF]

EClinicalMedicine
Tzang CC, Wu PH, Luo CA, Chen ZT, Lee YT, Huang ES, Kang YF, Lin WC, Tzang BS, Hsu TC.   +9 more
europepmc   +1 more source

Artificial lipidation of proteins and peptides: from mechanism to clinical applications

The FEBS Journal, EarlyView.
Artificial lipidation transforms protein and peptide therapeutics by attaching fatty acid chains through reversible or permanent chemical strategies. This biomimetic approach delivers four key therapeutic advantages: extended circulation times (enabling weekly instead of daily dosing), alternative administration routes including oral delivery, precise ...
Jiaming Mu, Emily Vong, Sheiliza Carmali
wiley   +1 more source

Intractable Vomiting in the Setting of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist and Cannabis Usage. [PDF]

Cureus
DesRochers P, Kaiser L, Lee S, Perchetti GA, Lazarescu R.   +4 more
europepmc   +1 more source

Comparative analysis of metabolic and functional cardiac alterations in diet‐ and genetically induced mouse models of cardiac dysfunction

The FEBS Journal, EarlyView.
Dietary and genetic stress trigger different routes to heart failure. In mice, a carbohydrate‐free high‐fat diet caused mitochondrial dysfunction and impaired energy production with preserved pumping function, while genetic obesity led to heart enlargement, fibrosis, and reduced function.
Christiane Ott, Patricia Baumgarten, Thorsten Henning, Daniela Weber, Iwona Wallach, Jana Grune, Ulrich Kintscher, Hermann‐Georg Holzhütter, Tilman Grune, Nikolaus Berndt   +9 more
wiley   +1 more source

GLP-1 Receptor Agonist Indications and Prescriptions Among Adults Who Do and Do Not Smoke. [PDF]

Diabetes Care
Leavens ELS, Arnold MJ, Nollen NL, Sanderson Cox L, Brown KA, Ellerbeck EF.   +5 more
europepmc   +1 more source